Previous close | 3.1000 |
Open | 5.0000 |
Bid | 2.9300 |
Ask | 3.0000 |
Strike | 140.00 |
Expiry date | 2024-06-21 |
Day's range | 3.0600 - 5.5200 |
Contract range | N/A |
Volume | |
Open interest | 1.67k |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.